No Data
Minsheng Securities: In 24Q3, the commercial retail industry in the consumer sector was affected by demand-side pressure, leading to a slowdown in revenue and profit growth across multiple sectors.
The total retail sales of 24 companies in Q1-Q3 reached 35.36 trillion yuan, with a year-on-year growth of +3.35%. The total retail sales of a single company in Q3 reached 11.76 trillion yuan, with a year-on-year growth of +2.69%, showing a slower growth rate compared to the previous quarter.
Pinning Down JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) P/S Is Difficult Right Now
Announcement of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. on the main operating data from January to September 2024
Jiangsu Wu Zhong Medicine Development Co., Ltd. Report for the third quarter of 2024
The launch of new medical beauty products contributed to performance, jiangsu wuzhong pharmaceutical development's net profit in the first three quarters increased by more than three times. | Interpretations
① In the first three quarters, jiangsu wuzhong pharmaceutical development's net profit attributable to the parent company increased by 311.54% year-on-year; ② The significant increase in performance during the reporting period of the AestheFill aesthetic facial filler contributed mainly to the company's performance growth; ③ The decline in the pharmaceutical sector business continues to expand.
Jiangsu Wuzhong Pharmaceutical Development (600200.SH) released its performance for the first three quarters, with a net income of 45.0806 million yuan, a year-on-year increase of 311.54%.
Jiangsu Wuzhong Pharmaceutical Development (600200.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Investors Aren't Buying JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) RevenuesNo Data
No Data
